Post-marketing Surveillance (Special Use-results Surveillance) on Treatment With Alhemo
Special Use-results Surveillance on Use of Alhemo in Patients With Haemophilia A or Haemophilia B Without Inhibitors A Multi-centre, Open-label, Non-interventional Post-marketing Study to Investigate the Long-term Safety and Clinical Parameters of Treatment With Alhemo in Patients With Haemophilia A or Haemophilia B Without Inhibitors in Routine Clinical Practice Conditions in Japan
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Novo Nordisk
- Phone Number: (+1) 866-867-7178
- Email: clinicaltrials@novonordisk.com
Study Locations
-
-
-
Chiba, Japan, 260-8677
- Chiba university hospital_Pediatrics
-
Fukui, Japan, 910-4272
- National Hospital Organization Awara Hospital_Hematology and Oncology
-
Fukushima, Japan, 963-8501
- Hoshi General Hospital_Pediatrics
-
Hyōgo, Japan, 660-8550
- Hyogo Prefectural Amagasaki General Medical Center_Haematology
-
Kanagawa, Japan, 216-8511
- St. Marianna University School of Medicine Hospital_Pediatrics
-
Kawagoe, Japan
- Saitama Medical Univ. Hospital Saitama medical center_Department of Transfusion Medicine and Cell Therapy
-
Miyagi, Japan, 989-3126
- Miyagi Children's Hospital_Hematology-Oncology
-
Nagano, Japan, 399-8288
- Nagano Children's Hospital_Hematology-Oncology
-
Nahano, Japan, 380-8582
- Nagano red cross hospital_Pediatrics
-
Okinawa, Japan, 901-1193
- Nanbu Medical Center & Children's Medical Center_Pediatric Hematology
-
Okinawa, Japan, 901-2132
- Arin Clinic Shonika_Pediatrics
-
Okinawa, Japan, 901-2725
- University of the Ryukyus Hospital_Endocrinology and Metabolism, Hematology and Rheumatology
-
Osaka, Japan, 573-1191
- Kansai Medical University Hospital_Pediatrics
-
Saitama, Japan, 330-8777
- Saitama Children's Med Centre_Hematology-Oncology
-
Saitama, Japan, 350-8550
- Saitama Medical Univ. Hospital Saitama medical center_Department of Transfusion Medicine and Cell Therapy
-
Saitama, Japan, 366-0052
- Fukaya Red Cross Hospital_Haematology
-
Shimane, Japan, 690-8506
- Matsue red cross hospital_Pediatrics
-
Shizuoka, Japan, 432-8580
- Hamamatsu Medical Center_Pediatrics
-
Shizuoka, Japan, 438-8550
- Iwata City Hospital_Haematology
-
Tokyo, Japan, 157-8535
- National Center for Child Health and Development_Hematology
-
Tokyo, Japan, 167-0035
- Ogikubo Hospital_Blood Coagulation
-
Yamagata, Japan, 992-0035
- Ishiyama Clinic
-
Yokohama-shi, Kanagawa, Japan, 241-0811
- St. Marianna Univ., Yokohama City Seibu HP, Pediatrics Dept,
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
- The decision to initiate treatment with commercially available Alhemo has been made by the participant/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the participant in this study.
- Male or female, age above or equal to 12 years at the time of signing informed consent.
- Diagnosis with Haemophilia A (HA) or Haemophilia B (HB).
- Participant who has never been exposed to concizumab or who starts treatment with concizumab within the past 12 weeks at registration.
Exclusion Criteria:
- Previous participation in this study. Participation is defined as having given informed consent in this study.
- Treatment with any investigational drug within 30 days prior to baseline (the starting date of Alhemo treatment).
- Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
- A history of hypersensitivity to any ingredients of Alhemo.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Concizumab
Participants with haemophilia A or haemophilia B without inhibitors will be be treated with commercially available Alhemo according to routine clinical practice at the discretion of the treating physician.
|
Participants will be treated with commercially available Alhemo according to routine clinical practice at the discretion of the treating physician.
Administration will be according to the approved product labelling.
The decision to treat a participant with Alhemo is made at the physician's discretion before and independently from this study.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of adverse reaction (AR)
Time Frame: From baseline (week 0) to end of study (week 104)
|
Count of adverse reaction.
|
From baseline (week 0) to end of study (week 104)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of serious adverse reaction (SAR)
Time Frame: From baseline (week 0) to end of study (week 104)
|
Count of serious adverse reaction.
|
From baseline (week 0) to end of study (week 104)
|
|
Number of serious adverse event (SAE)
Time Frame: From baseline (week 0) to end of study (week 104)
|
Count of serious adverse event.
|
From baseline (week 0) to end of study (week 104)
|
|
Number of thromboembolic adverse event (AE)
Time Frame: From baseline (week 0) to end of study (week 104)
|
Count of thromboembolic adverse event.
|
From baseline (week 0) to end of study (week 104)
|
|
Number of shock/anaphylaxis adverse event (AE)
Time Frame: From baseline (week 0) to end of study (week 104)
|
Count of shock/anaphylaxis adverse event.
|
From baseline (week 0) to end of study (week 104)
|
|
Number of treated spontaneous and traumatic bleeding episodes
Time Frame: From baseline (week 0) to end of study (week 104)
|
Count of treated spontaneous and traumatic bleeding episodes.
|
From baseline (week 0) to end of study (week 104)
|
|
Number of treated spontaneous and traumatic target joint bleeding episodes
Time Frame: From baseline (week 0) to end of study (week 104)
|
Count of treated spontaneous and traumatic target joint bleeding episodes.
|
From baseline (week 0) to end of study (week 104)
|
|
Number of all treatment requiring bleeding episodes
Time Frame: From baseline (week 0) to end of study (week 104)
|
Count of all treatment requiring bleeding episodes.
|
From baseline (week 0) to end of study (week 104)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Genetic Diseases, Inborn
- Hematologic Diseases
- Blood Coagulation Disorders
- Hemorrhagic Disorders
- Genetic Diseases, X-Linked
- Blood Coagulation Disorders, Inherited
- Coagulation Protein Disorders
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities
- Hemic and Lymphatic Diseases
- Hemophilia A
- Hemophilia B
- concizumab
Other Study ID Numbers
Other Study ID Numbers
- NN7415-7690
- U1111-1286-2960 (Other Identifier: Universal trial number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.